HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Immunotherapy induced hypophysitis — Clinical Guidelines

Overview

Immunotherapy-induced hypophysitis is an endocrine complication characterized by inflammation of the pituitary gland, often triggered by immune checkpoint inhibitors (ICIs) used in cancer treatment, leading to hormonal imbalances and various clinical manifestations. 8

Diagnosis

Clinical symptoms include fatigue, amenorrhea, hypothyroidism, and adrenal insufficiency.

Elevated inflammatory markers may be present.

Imaging studies (MRI) often reveal pituitary enlargement or inflammation.

Hormonal assessments (FSH, LH, TSH, cortisol, ACTH) are crucial for diagnosis. 8

Management

First-line treatment: High-dose glucocorticoids (e.g., prednisone) to reduce inflammation. 8

Adjunctive therapies: Hormone replacement therapy tailored to specific deficiencies (e.g., levothyroxine for hypothyroidism, hydrocortisone for adrenal insufficiency).

Monitoring: Regular follow-up with endocrinological evaluations to adjust hormone replacement as needed. 8

Special Populations

Pregnancy: Limited data; management should focus on balancing maternal and fetal health with close endocrinological monitoring. 8

Elderly: Increased vigilance for complications due to potential comorbidities and altered pharmacokinetics; individualized treatment plans are essential. 8

Key Recommendations

Initiate high-dose glucocorticoids promptly upon suspicion of ICI-induced hypophysitis to manage inflammation. (Evidence: Strong 8)

Implement comprehensive hormonal assessments to guide specific hormone replacement therapy. (Evidence: Strong 8)

Regularly monitor patients for both endocrine function and response to treatment, adjusting therapies as necessary. (Evidence: Moderate 8)

Consider individualized treatment approaches in special populations such as the elderly due to increased risk of comorbidities. (Evidence: Expert opinion 8)

References

1 Fregnani ER, Epstein JB, Blijlevens NMA, Yarom N, Villa A, Raber-Durlacher JE et al.. MASCC/ISOO Clinical Practice Statement: management of oral complications of immunotherapy. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2025. link 2 Okada N, Yanagi T, Sasaki T, Tamura M, Ozaki M, Saisyo A et al.. Association between immune checkpoint inhibitor and cytomegalovirus infection: A pharmacovigilance study based on the adverse event reporting system. International journal of cancer 2025. link 3 Yao G, Zhang Y, Zhang H, Tang L, Ding C, Zhou X. Immune checkpoint inhibitor-associated myocarditis and pericarditis: a pharmacovigilance study based on the FAERS database. BMC cancer 2025. link 4 Thompson JA, Schneider BJ, Brahmer J, Zaid MA, Achufusi A, Armand P et al.. NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024. Journal of the National Comprehensive Cancer Network : JNCCN 2024. link 5 Handke A, Hilser T, Bögemann M, Schlack K, Grünwald V. [Emergencies in cancer immunotherapy]. Aktuelle Urologie 2024. link 6 L'Orphelin JM, Da Silva A, Cabon J, Alexandre J, Dolladille C. Immune checkpoint inhibitor rechallenge after immune-related adverse events: a retrospective study from VigiBase update in 2024 looking for emergent safety signals. BMJ open 2024. link 7 Peterson C. Management of Immunotherapy Infusion Reactions. Clinical journal of oncology nursing 2023. link 8 Deshmukh VC. Management of Immune Checkpoint Inhibitor-Associated Endocrinopathies: A Tight Rope Walk. JCO oncology practice 2023. link 9 . The BEHAV3D Platform Demonstrates Cellular Immunotherapy Modes of Action. Cancer discovery 2022. link 10 Couzin-Frankel J. Researchers tackle vexing side effects of potent cancer drugs. Science (New York, N.Y.) 2022. link 11 Sun MM, Kelly SP, Mylavarapu Bs AL, Holland GN, Coleman AL, Yu F et al.. Ophthalmic Immune-Related Adverse Events after Anti-CTLA-4 or PD-1 Therapy Recorded in the American Academy of Ophthalmology Intelligent Research in Sight Registry. Ophthalmology 2021. link 12 Makunts T, Saunders IM, Cohen IV, Li M, Moumedjian T, Issa MA et al.. Myocarditis occurrence with cancer immunotherapy across indications in clinical trial and post-marketing data. Scientific reports 2021. link 13 Köstek O, Demir T. Sarcopenia and Inflammation with Immunotherapy. The oncologist 2020. link 14 Bilen MA, Master VA, Harvey RD. In Reply. The oncologist 2020. link 15 Curran M, Mairesse M, Matas-Céspedes A, Bareham B, Pellegrini G, Liaunardy A et al.. Recent Advancements and Applications of Human Immune System Mice in Preclinical Immuno-Oncology. Toxicologic pathology 2020. link 16 Chen G, Qin Y, Fan QQ, Zhao B, Mei D, Li XM. Renal adverse effects following the use of different immune checkpoint inhibitor regimens: A real-world pharmacoepidemiology study of post-marketing surveillance data. Cancer medicine 2020. link 17 Subbiah V, Kurzrock R. The Marriage Between Genomics and Immunotherapy: Mismatch Meets Its Match. The oncologist 2019. link 18 . A Rethink for IO Biomarkers. Cancer discovery 2018. link 19 Alsufyani F, Pillai S. JAKing up resistance to immunotherapy. Science immunology 2017. link 20 Cappelli LC, Shah AA, Bingham CO. Immune-Related Adverse Effects of Cancer Immunotherapy- Implications for Rheumatology. Rheumatic diseases clinics of North America 2017. link 21 Lomax AJ, McNeil C. Acute management of autoimmune toxicity in cancer patients on immunotherapy: Common toxicities and the approach for the emergency physician. Emergency medicine Australasia : EMA 2017. link 22 Davis ME, Francis JH. Cancer Therapy with Checkpoint Inhibitors: Establishing a Role for Ophthalmology. Seminars in oncology nursing 2017. link 23 Wanchoo R, Karam S, Uppal NN, Barta VS, Deray G, Devoe C et al.. Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review. American journal of nephrology 2017. link 24 Breiner K. Phacilitate Immunotherapy Leaders' Forum: How to tap into dilutive and non-dilutive funding sources for immunotherapy projects--Barcelona, May 9-11, 2012. Human vaccines & immunotherapeutics 2012. link 25 Cook PR, Bryant JL, Davis WE, Benke TT, Rapoport AS. Systemic reactions to immunotherapy: the American Academy of Otolaryngic Allergy morbidity and mortality survey. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery 1994. link 26 Friis EV, Frederiksen M, Simonsen EE. Anaphylactic reaction during immunotherapy related to alcohol consumption. Allergy 1992. link

Immunotherapy induced hypophysitis